TVMR With the INNOVALVE System Trial - Early Feasibility Study
← catalyst calendarSponsored by Edwards Lifesciences (industry) · EW — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
65estimated
Sites
20
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-09-01 | actual | When the study began enrolling |
| Primary completion | 2026-07-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-07-01 | estimated | The whole study's end, after follow-up |
| First posted | 2021-06-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Mitral Valve Regurgitation (Degenerative or Functional)
Intervention
- Device: INNOVALVE system
Primary outcome
what the primary-completion date above is the date OFAbsence of implant or delivery related serious adverse events at 30 Days
measured 30 days
Permalink · EW's whole pipeline · Catalyst calendar · Every registered study · What changed